TNBC, by definition, lacks the three typical surface markers and is thus refractory to common therapeutic targets of breast cancer, including the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), which severely limits its therapeutic options and justifies continued efforts to develop additional TNBC-specific treatments. The gene discussed is ERBB2; the disease is breast cancer.